Charles Burdet
Charles Burdet
Inserm UMR 1137 "IAME". Infection. Antimicrobials. Modeling. Evolution
Adresse e-mail validée de
Citée par
Citée par
Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M
PL Woerther, C Burdet, E Chachaty, A Andremont
Clinical microbiology reviews 26 (4), 744-758, 2013
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ...
Science immunology 6 (62), eabl4340, 2021
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled …
F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ...
The Lancet infectious diseases 22 (2), 209-221, 2022
X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19
T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ...
Science immunology 6 (62), eabl4348, 2021
Protection of the human gut microbiome from antibiotics
J De Gunzburg, A Ghozlane, A Ducher, E Le Chatelier, X Duval, E Ruppé, ...
The Journal of infectious diseases 217 (4), 628-636, 2018
Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia
G Voiriot, B Visseaux, J Cohen, LBL Nguyen, M Neuville, C Morbieu, ...
Critical Care 20, 1-9, 2016
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ...
Proceedings of the National Academy of Sciences 119 (21), 2022
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled …
A Dinh, J Ropers, C Duran, B Davido, L Deconinck, M Matt, O Senard, ...
The Lancet 397 (10280), 1195-1203, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
F Ader, N Peiffer-Smadja, J Poissy, M Bouscambert-Duchamp, D Belhadi, ...
Clinical Microbiology and Infection 27 (12), 1826-1837, 2021
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)
V Joly, C Burdet, R Landman, M Vigan, C Charpentier, C Katlama, ...
Journal of Antimicrobial Chemotherapy 74 (3), 739-745, 2019
High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure: the COVIDICUS randomized …
L Bouadma, A Mekontso-Dessap, C Burdet, H Merdji, J Poissy, C Dupuis, ...
JAMA internal medicine 182 (9), 906-916, 2022
Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France
P Loubet, N Lenzi, M Valette, V Foulongne, A Krivine, N Houhou, ...
Clinical Microbiology and Infection 23 (4), 253-259, 2017
Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016
B Visseaux, C Burdet, G Voiriot, FX Lescure, T Chougar, O Brugière, ...
PLoS One 12 (7), e0180888, 2017
Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review
P Loubet, C Burdet, W Vindrios, N Grall, M Wolff, Y Yazdanpanah, ...
Clinical microbiology and infection 24 (2), 125-132, 2018
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives
Q Le Hingrat, B Visseaux, C Laouenan, S Tubiana, L Bouadma, ...
Clinical Microbiology and Infection 27 (5), 789. e1-789. e5, 2021
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
A Amstutz, B Speich, F Mentré, CS Rueegg, D Belhadi, L Assoumou, ...
The Lancet Respiratory Medicine 11 (5), 453-464, 2023
Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation …
PL Woerther, R Lepeule, C Burdet, JW Decousser, É Ruppé, F Barbier
International journal of antimicrobial agents 52 (6), 762-770, 2018
Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage
E Ruppé, C Burdet, N Grall, V De Lastours, FX Lescure, A Andremont, ...
Clinical Microbiology and Infection 24 (1), 3-5, 2018
Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening
T Hueso, K Ekpe, C Mayeur, A Gatse, M Joncquel-Chevallier Curt, ...
Gut microbes 12 (1), 1800897, 2020
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia
C Burdet, O Pajot, C Couffignal, L Armand-Lefèvre, A Foucrier, ...
European journal of clinical pharmacology 71, 75-83, 2015
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20